IBM Watson Health and Aetion will combine the Aetion Evidence Platform® with IBM MarketScan data to provide a turn-key solution for conducting regulatory-grade RWE analysis. The partnership will satisfy mid-market companies’ demand to streamline the drug R&D process and allow RWE to play a much greater role in supporting companies’ drug portfolios.
Read More
Read More